Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic...

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Pancreatic cancer features an immunosuppressive tumor microenvironment driven by cytokines like IL-1.
• The IL-1/IL-1R axis promotes Th2 and Th17 inflammation, crucial for tumor progression.
• Cancer-associated fibroblasts (CAFs) secrete TSLP, polarizing dendritic cells towards Th2 responses.

Purpose of the Study:

• To develop and evaluate ANK-loaded sphingomyelin nanosystems (ANK-SNs) for pancreatic cancer therapy.
• To compare the efficacy of ANK-SNs against free ANK in inhibiting Th2 and Th17 inflammation in vitro.
• To assess the impact of ANK-SNs on cytokine secretion by CAFs and Th17 cells.

Main Methods:

• Development of sphingomyelin nanosystems (SNs) loaded with anakinra (ANK).
• In vitro assessment of ANK-SNs' ability to inhibit TSLP and pro-tumor cytokines from CAFs.
• Evaluation of ANK-SNs' efficacy in suppressing IL-17 and interferon-γ secretion by Th17 cells.

Main Results:

• ANK-SNs demonstrated comparable inhibition of TSLP and pro-tumor cytokines from CAFs as free ANK.
• ANK-SNs achieved significantly higher inhibition of IL-17 secretion by Th17 cells at lower concentrations compared to ANK.
• Interferon-γ secretion by Th17 cells was not significantly affected by ANK-SNs.

Conclusions:

• ANK-SNs represent a promising nanocarrier for IL-1 receptor antagonist delivery in pancreatic cancer.
• This nanotechnology may enhance therapeutic efficacy by improving drug targeting and reducing required dosage.
• ANK-SNs hold potential for mitigating drug-related toxicities in pancreatic cancer treatment.